NMPA Issues Export Drug Certification Rules, Expanding Scope and Validity
China’s National Medical Products Administration (NMPA) released the “Regulations on Inspection and Export Certification Management...
NMPA
NMPA Releases 98th RLD Catalog for Chemical Generics, Adding 48 New Specifications
China’s National Medical Products Administration (NMPA) released the ninety-eighth batch of the Reference Listed Drugs...
Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program
The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...
China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs
The China Center for Drug Evaluation (CDE) has released a draft list of the 100th...
NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
The National Medical Products Administration (NMPA) today issued the “Measures for the Administration of Drug...
NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...
China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...
NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...
China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings
The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...
NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight
The National Medical Products Administration (NMPA) issued a draft of its Compliance Guidelines for Online...
NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs
The National Medical Products Administration (NMPA) today announced the release of its 95th Reference‑Listed Drugs...
China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications
China’s National Medical Products Administration (NMPA) announced on August 20, 2025, that it had resumed...
InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors
China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...
NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services
On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...
NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...
NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications
The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...
NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...
NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation
China’s National Medical Products Administration (NMPA) last week released the “Measures to Optimize Full-lifecycle Regulation...
NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...
CDE Issues New Requirements for IND Applications of Innovative Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...